SCHEMBL4168959

SCHEMBL4168959

N#Cc1cc(O)c(O)c(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
TTR P02766 2/20 0.56
ALB P02768 2/20 0.56
PTPN11 Q06124 1/20 0.47
KDM4E B2RXH2 4/20 0.44
MAPT P10636 4/20 0.44
EGFR P00533 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
BLM P54132 3/20 0.44
ALDH1A1 P00352 3/20 0.44
TP53 P04637 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RGS12 O14924 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366982 0.85 TTR (0.48) MEN1KMT2ATTRALBPTPN11
SCHEMBL20906090 0.83 TTR (0.78) MEN1KMT2ATTRALBPTPN11
SCHEMBL27755117 0.83 TTR (0.52) MEN1KMT2ATTRALBPTPN11
SCHEMBL30689086 0.83 TTR (0.78) MEN1KMT2ATTRALBPTPN11
SCHEMBL12846356 0.79 EGFR (0.51) MEN1KMT2ATTRALBKDM4E
SCHEMBL198609 0.78 TTR (0.52) MEN1KMT2ATTRALBPTPN11
SCHEMBL31014054 0.78 TTR (0.58) MEN1KMT2ATTRALBPTPN11
SCHEMBL6748702 0.78 TTR (0.47) MEN1KMT2ATTRALBPTPN11
SCHEMBL27342130 0.78 XDH (0.50) MEN1KMT2ATTRALBSELL
SCHEMBL18002603 0.78 TTR (0.41) MEN1KMT2ATTRALBPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1540680-A1 N-TYPE METAL OXIDE SEMICONDUCTOR SPECTRALLY SENSITIZED WITH A CATIONIC SPECTRAL SENSITIZER Agfa-Gevaert (BE) 2005-06-15 EP claimed
US-20040094198-A1 n-type Metal oxide semiconductor spectrally sensitized with a cationic spectral sensitizer AGFA-GEVAERT (BE) 2004-05-20 US claimed
WO-2004025674-A1 N-TYPE METAL OXIDE SEMICONDUCTOR SPECTRALLY SENSITIZED WITH A CATIONIC SPECTRAL SENSITIZER AGFA-GEVAERT (BE) 2004-03-25 WO claimed
US-20170100352-A1 Methods for treating or preventing neuroinflammation or autoimmune diseases ELFORD HOWARD L (US) 2017-04-13 US disclosed
US-9526707-B2 Methods for treating or preventing neuroinflammation or autoimmune diseases ELFORD HOWARD L (US) 2016-12-27 US disclosed
EP-2030615-A2 Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases ELFORD, Howard L. (US) 2009-03-04 EP disclosed
US-20090047250-A1 Methods for treating or preventing neuroinflammation or autoimmune diseases ELFORD HOWARD L 2009-02-19 US disclosed
EP-1540680-A1 N-TYPE METAL OXIDE SEMICONDUCTOR SPECTRALLY SENSITIZED WITH A CATIONIC SPECTRAL SENSITIZER Agfa-Gevaert (BE) 2005-06-15 EP disclosed
US-20040094198-A1 n-type Metal oxide semiconductor spectrally sensitized with a cationic spectral sensitizer AGFA-GEVAERT (BE) 2004-05-20 US disclosed
WO-2004025674-A1 N-TYPE METAL OXIDE SEMICONDUCTOR SPECTRALLY SENSITIZED WITH A CATIONIC SPECTRAL SENSITIZER AGFA-GEVAERT (BE) 2004-03-25 WO disclosed
US-5183828-A Ribonucleotide reductase inhibitor and free radical scavenger RIET BARTHOLOMEUS VAN T (US) 1993-02-02 US disclosed
US-5087548-A POSITIVE TYPE RADIATION-SENSITIVE RESIN COMPOSITION JAPAN SYNTHETIC RUBBER CO., INC. (JP) 1992-02-11 US disclosed
EP-0144396-B1 POLYHYDROXYBENZOIC ACID DERIVATIVES VAN'T RIET, Bartholomeus (US) 1991-01-02 EP disclosed
US-4942253-A INHIBITORS OF RIBONUCLEOTIDE REDUCTASE, ANTITUMOR AGENTS, LEUKEMIA, FREE RADICAL SCAVENGERS RIET BARTHOLOMEUS VAN T (US) 1990-07-17 US disclosed
EP-0227487-A2 Positive type radiation-sensitive resin composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1987-07-01 EP disclosed
US-4623659-A RIBONUCLEOTIDE REDUCTASE INHIBITORS RIET BARTHOLOMEUS VAN T (US) 1986-11-18 US disclosed
EP-0144396-A4 POLYHYDROXYBENZOIC ACID DERIVATIVES. RIET BARTHOLOMEUS VAN T (US) 1986-08-21 EP disclosed
EP-0144396-A1 POLYHYDROXYBENZOIC ACID DERIVATIVES. RIET BARTHOLOMEUS VAN T (US) 1985-06-19 EP disclosed
WO-1984004676-A1 POLYHYDROXYBENZOIC ACID DERIVATIVES RIET BARTHOLOMEUS VAN T 1984-12-06 WO disclosed
US-4418037-A PYROGALLOL DERIVATIVE STORAGE STABILIZER FUJI PHOTO FILM CO., LTD. (JP) 1983-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047250-A1 Methods for treating or preventing neuroinflammation or autoimmune diseases RNASE1, RNASEH1, TXNRD3 MEN1 4476/4885KMT2A 2581/4885TTR 128/4885
US-20170100352-A1 Methods for treating or preventing neuroinflammation or autoimmune diseases RNASE1, RNASEH1, TXNRD3 MEN1 4476/4885KMT2A 2581/4885TTR 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.